Zobrazeno 1 - 9
of 9
pro vyhledávání: '"Masamitsu Hihara"'
Autor:
Jun Watanabe, Kei Muro, Kohei Shitara, Kentaro Yamazaki, Manabu Shiozawa, Hisatsugu Ohori, Atsuo Takashima, Mitsuru Yokota, Akitaka Makiyama, Naoya Akazawa, Hitoshi Ojima, Yasuhiro Yuasa, Keisuke Miwa, Hirofumi Yasui, Eiji Oki, Takeo Sato, Takeshi Naitoh, Yoshito Komatsu, Takeshi Kato, Masamitsu Hihara, Junpei Soeda, Toshihiro Misumi, Kouji Yamamoto, Kiwamu Akagi, Atsushi Ochiai, Hiroyuki Uetake, Katsuya Tsuchihara, Takayuki Yoshino
Publikováno v:
JAMA. 329:1271
ImportanceFor patients with RAS wild-type metastatic colorectal cancer, adding anti–epidermal growth factor receptor (anti-EGFR) or anti–vascular endothelial growth factor (anti-VEGF) monoclonal antibodies to first-line doublet chemotherapy is ro
Autor:
Atsushi Ochiai, Junpei Soeda, Kohei Shitara, Hiroyuki Uetake, Kiwamu Akagi, Katsuya Tsuchihara, Takeharu Yamanaka, Takeshi Naitoh, Kentaro Yamazaki, Masamitsu Hihara, Eiji Oki, Yoshito Komatsu, Jun Watanabe, Ikuo Mori, Takayuki Yoshino, Kazunori Yamanaka, Kei Muro, Takeo Sato, Takeshi Kato
Publikováno v:
Journal of Clinical Oncology. 39:85-85
85 Background: The optimal choice of monoclonal antibodies (mAbs) for first-line treatment in patients (pts) with RAS ( KRAS/NRAS) wild-type metastatic colorectal cancer (mCRC) remains controversial. The meta-analyses of subgroup analyses in phase II
Autor:
Hiroyuki Uetake, Kohei Shitara, Takayuki Yoshino, Kei Muro, Kiwamu Akagi, Hirofumi Yasui, Jun Watanabe, Takeo Sato, Takeharu Yamanaka, Kentaro Yamazaki, Takeshi Kato, Manabu Shiozawa, Kazunori Yamanaka, Riu Yamashita, Eiji Oki, Victor E. Velculescu, Hisatsugu Ohori, Atsushi Ochiai, Junpei Soeda, Masamitsu Hihara, Yoshito Komatsu, Ikuo Mori, Katsuya Tsuchihara, Takeshi Naitoh
Publikováno v:
Cancer Research. 80:1974-1974
Introduction: We performed an exploratory analysis of circulating tumor DNA (ctDNA) in patients (pts) with RAS wild-type (WT) chemotherapy-naïve stage IV metastatic colorectal cancer (mCRC) from the ongoing phase III PARADIGM study (NCT02394834). Th
Autor:
Hiroyuki Uetake, Takeharu Yamanaka, Atsushi Ochiai, Takeo Sato, Kiwamu Akagi, Kentaro Yamazaki, Kazunori Yamanaka, Eiji Oki, Takayuki Yoshino, T. Kato, Junpei Soeda, Katsuya Tsuchihara, Takeshi Naitoh, Mitsuyoshi Ota, Kohei Shitara, Masamitsu Hihara, Yoshito Komatsu, Ikuo Mori, K. Muro
Publikováno v:
Annals of Oncology. 30:iv10
Autor:
Takayuki Yoshino, Kei Muro, Eiji Oki, Kazunori Yamanaka, Takeharu Yamanaka, Masamitsu Hihara, Kentaro Yamazaki, Kohei Shitara, Katsuya Tsuchihara, Yoshito Komatsu, Hiroyuki Uetake, Kouji Iwasaki, Jumpei Soeda, Takeshi Naitoh, Takeo Sato, Takeshi Kato, Atsushi Ochiai
Publikováno v:
Clinical colorectal cancer. 16(2)
Background It remains unclear whether an anti-VEGF or anti-EGFR antibody with standard doublet chemotherapy is the optimal first-line treatment in patients with RAS ( KRAS/NRAS ) wild-type metastatic colorectal cancer (mCRC). Here we outline the PARA
Autor:
Kohei Shitara, Kazunori Yamanaka, Takayuki Yoshino, Hyunjin Shin, Katsuya Tsuchihara, Kei Muro, Takeharu Yamanaka, Sunita Badola, Atsushi Ochiai, Masamitsu Hihara, Kentaro Yamazaki, Yoshito Komatsu, Hiroyuki Uetake, Ikuo Mori, Kiwamu Akagi, Mitsuyoshi Ota, Eiji Oki, Takeo Sato, Takeshi Kato, Jumpei Soeda, Takeshi Naitoh
Publikováno v:
Cancer Research. 78:CT164-CT164
Introduction Circulating tumor DNA (ctDNA) is an emerging biomarker used to track disease progression and treatment response. To investigate mechanisms of resistance to panitumumab and bevacizumab, we performed an exploratory analysis of ctDNA from p
Autor:
Kei Muro, Hiroyuki Uetake, Katsuya Tsuchihara, Kohei Shitara, Kentaro Yamazaki, Eiji Oki, Takeo Sato, Takeshi Naitoh, Yoshito Komatsu, Takeshi Kato, Kouji Iwasaki, Junpei Soeda, Masamitsu Hihara, Takeharu Yamanaka, Atsushi Ochiai, Takayuki Yoshino
Publikováno v:
Journal of Clinical Oncology. 34:TPS3625-TPS3625
Autor:
Atsushi Ochiai, Takeshi Naitoh, Kouji Iwasaki, Takeharu Yamanaka, Masamitsu Hihara, Eiji Oki, Katsuya Tsuchihara, Kohei Shitara, Junpei Soeda, Yoshito Komatsu, Takayuki Yoshino, Takeo Sato, Takeshi Kato, Hiroyuki Uetake, Kei Muro, Kentaro Yamazaki
Publikováno v:
Journal of Clinical Oncology. 34:TPS776-TPS776
TPS776 Background: Optimal combination of monoclonal antibody (anti-VEGF vs. anti-EGFR antibody) with standard chemotherapy as first-line treatment in patients (pts) with RAS (KRAS/NRAS) wild-type metastatic colorectal cancer (mCRC) remains controver
Autor:
Takayuki Yoshino, Hiroyuki Uetake, Katsuya Tsuchihara, Kohei Shitara, Kentaro Yamazaki, Eiji Oki, Takeo Sato, Takeshi Naitoh, Yoshito Komatsu, Takeshi Kato, Kazunori Yamanaka, Kouji Iwasaki, Jumpei Soeda, Masamitsu Hihara, Takeharu Yamanaka, Atsushi Ochiai, Kei Muro, Yoshino, Takayuki, Uetake, Hiroyuki, Tsuchihara, Katsuya
Publikováno v:
Clinical Colorectal Cancer; Jun2017, Vol. 16 Issue 2, p158-163, 6p